0.00Open0.00Pre Close0 Volume0 Open Interest100.00Strike Price0.00Turnover150.00%IV-59.17%PremiumDec 20, 2024Expiry Date144.89Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9914Delta0.0002Gamma1.68Leverage Ratio-0.0528Theta0.0737Rho1.67Eff Leverage0.0157Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet